ProQR Therapeutics NV (PRQR):企業の財務・戦略的SWOT分析

◆英語タイトル:ProQR Therapeutics NV (PRQR) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH452686FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ProQR Therapeutics NV (ProQR) is a clinical-stage biotech company that discovers and develops drugs for the treatment of genetic disorders. The company’s lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber’s congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa. It develops novel investigational drug called QR-421 for the treatment of usher syndrome, fuchs endothelial corneal dystrophy, dystrophic epidermolysis bullosa, alzheimer’s disease, central nervous system and neuromuscular diseases. The company also offers clinical trial services. It operates through its laboratory and offices located in Leiden. It operates offices in the US and the Netherlands. ProQR is headquartered in Leiden, the Netherlands.

ProQR Therapeutics NV Key Recent Developments

Mar 02,2021: ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference
Feb 25,2021: ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
Nov 16,2020: ProQR announces third quarter 2020 operating and financial results
Oct 05,2020: ProQR appoints Naveed Shams, MD, PhD as Chief Scientific Officer
Aug 06,2020: ProQR announces second quarter 2020 operating and financial results

This comprehensive SWOT profile of ProQR Therapeutics NV provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of ProQR Therapeutics NV including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

ProQR Therapeutics NV – Key Information
ProQR Therapeutics NV – Overview
ProQR Therapeutics NV – Key Employees
ProQR Therapeutics NV – Key Employee Biographies
ProQR Therapeutics NV – Key Operational Heads
ProQR Therapeutics NV – Major Products and Services
ProQR Therapeutics NV – History
ProQR Therapeutics NV – Company Statement
ProQR Therapeutics NV – Locations And Subsidiaries
ProQR Therapeutics NV
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

ProQR Therapeutics NV – Business Description
ProQR Therapeutics NV – Corporate Strategy
ProQR Therapeutics NV – SWOT Analysis
SWOT Analysis – Overview
ProQR Therapeutics NV – Strengths
ProQR Therapeutics NV – Weaknesses
ProQR Therapeutics NV – Opportunities
ProQR Therapeutics NV – Threats
ProQR Therapeutics NV – Key Competitors

Section 3 – Company Financial Performance Charts

ProQR Therapeutics NV – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

ProQR Therapeutics NV, Key Information
ProQR Therapeutics NV, Key Ratios
ProQR Therapeutics NV, Share Data
ProQR Therapeutics NV, Major Products and Services
ProQR Therapeutics NV, History
ProQR Therapeutics NV, Key Employees
ProQR Therapeutics NV, Key Employee Biographies
ProQR Therapeutics NV, Key Operational Heads
ProQR Therapeutics NV, Other Locations
ProQR Therapeutics NV, Subsidiaries
ProQR Therapeutics NV, Key Competitors
ProQR Therapeutics NV, SWOT Analysis
ProQR Therapeutics NV, Ratios based on current share price
ProQR Therapeutics NV, Annual Ratios
ProQR Therapeutics NV, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[ProQR Therapeutics NV (PRQR):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Shenogen Pharma Group Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Shenogen Pharma Group Ltd (Shenogen) is a drug discovery and development company that develops therapeutics for cancer treatment. The company develops biologic drugs and small molecule targeted at the new estrogen receptor variant. It provides SNG-162 that is a small molecule naturally deriv …
  • Immunomedics Inc (IMMU):医療機器:M&Aディール及び事業提携情報
    Summary Immunomedics Inc (Immunomedics) is a clinical-stage bio-pharmaceutical company that researches, develops, manufactures and commercializes monoclonal antibody-based drugs for the treatment of cancer and autoimmune disorders. The company develops its candidates based on its proprietary technol …
  • Net Insight AB (NETI B):企業の財務・戦略的SWOT分析
    Net Insight AB (NETI B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Beverages & More Inc:企業の戦略的SWOT分析
    Beverages & More Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Coloplast A/S:企業の戦略・SWOT・財務情報
    Coloplast A/S - Strategy, SWOT and Corporate Finance Report Summary Coloplast A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • UGI Corporation (UGI)-石油・ガス分野:企業M&A・提携分析
    Summary UGI Corporation (UGI) is a holding company providing energy products and services. Through a network of subsidiaries, the company stores, transports, distributes and markets energy products and related services. It serves as a domestic and international retail distributor of propane and buta …
  • Wintershall Holding GmbH:企業の戦略的SWOT分析
    Wintershall Holding GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Ricerca Biosciences LLC-製薬・医療分野:企業M&A・提携分析
    Summary Ricerca Biosciences LLC (Ricerca), formerly Ricerca Inc, a subsidiary of Main Market Partners LLC, is a contract research organization that offers services to accelerate drug development. The organization's service portfolio includes drug safety and metabolism, chemical development, agrochem …
  • MBNA Ltd:企業の戦略・SWOT・財務情報
    MBNA Ltd - Strategy, SWOT and Corporate Finance Report Summary MBNA Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • OriGene Technologies Inc-医療機器分野:企業M&A・提携分析
    Summary OriGene Technologies Inc (OriGene) is a research tool company that develops cDNA. The company creates commercial collection of full-length human cDNAs in expression vector. It develops, manufactures and sells genome research and diagnostic products. OriGene’s products include qPCR reagents, …
  • Oswaldo Cruz Foundation:製薬・医療:M&Aディール及び事業提携情報
    Summary Oswaldo Cruz Foundation (Oswaldo Cruz) is a provider of research and development in biological sciences. It offers research programs and technological development projects in vaccines production, medications, drugs, reagents and diagnostic kits. The foundation provides research in experiment …
  • Australian Leaders Fund Limited:企業の戦略・SWOT・財務情報
    Australian Leaders Fund Limited - Strategy, SWOT and Corporate Finance Report Summary Australian Leaders Fund Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Time Technoplast Ltd:企業の戦略・SWOT・財務情報
    Time Technoplast Ltd - Strategy, SWOT and Corporate Finance Report Summary Time Technoplast Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Trivitron Healthcare Pvt Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Trivitron Healthcare Pvt Ltd (Trivitron) is a medical technology company that provides solutions to healthcare providers. The company’s products include radiography and c-arm systems, newborn screening, mammography, ultrasound, contrast media, breast biopsy system, bone densitometer, radiati …
  • Intuitive Surgical Inc (ISRG):企業の財務・戦略的SWOT分析
    Intuitive Surgical Inc (ISRG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Novaliq GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Novaliq GmbH (Novaliq) is a drug delivery company that develops pharmaceutical formulations. The company develops novel ophthalmic and dermatological products, and solutions for organ preservation based on the physicochemical properties of semifluorinated alkanes. It offers NovaTears, a pres …
  • Gevo Inc (GEVO):企業の財務・戦略的SWOT分析
    Summary Gevo Inc (Gevo) is a renewable chemicals and advanced biofuels company that offers renewable chemicals and biofuels. The company’s products include carbon cycle products, low carbon renewable jet fuels, renewable gasoline, isobutanol blendstocks, ingredient products, animal feed and proteins …
  • Redx Pharma Plc (REDX):製薬・医療:M&Aディール及び事業提携情報
    Summary Redx Pharma Plc (Redx Pharma), formerly Redx Pharma Ltd is a drug discovery and development company that develops early stage and small molecule therapeutics. The company’s pipeline products include inhibitors for oncology and anti-infectives for treatment of diseases that include influenza …
  • Nestle Australia Ltd:企業の戦略・SWOT・財務分析
    Nestle Australia Ltd - Strategy, SWOT and Corporate Finance Report Summary Nestle Australia Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Drexel University:製薬・医療:M&Aディール及び事業提携情報
    Summary Drexel University (Drexel) is a research university which provides educational degrees and research programs. The university offers courses for undergraduate courses, graduate and professional courses, adult education programs, colleges and schools, libraries and online training services. It …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆